For the quarter ending 2026-03-31, TNDM made $247,221K in revenue. -$20,942K in net income. Net profit margin of -8.47%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales | 247,221 | 290,383 | 249,253 | 240,678 |
| Cost of sales | 110,433 | 122,923 | 114,961 | 114,823 |
| Gross profit | 136,788 | 167,460 | 134,292 | 125,855 |
| Selling, general and administrative | 108,187 | 113,100 | 108,440 | 109,596 |
| Litigation and settlement expense | - | 0 | 0 | 19,951 |
| Research and development | 46,035 | 46,066 | 48,715 | 48,118 |
| Acquired in-process research and development expenses | 0 | 0 | 0 | 0 |
| Total operating expenses | 154,222 | 159,166 | 157,155 | 177,665 |
| Loss on extinguishment of debt | - | 0* | 0 | 0 |
| Operating gain | -17,434 | 8,294 | -22,863 | -51,810 |
| Interest income and other income, net | 3,626 | 3,016* | 2,509 | -632 |
| Interest expense | 2,204 | 2,075 | 2,065 | 1,905 |
| Loss from equity method investments | -3,865 | -4,553 | -2,724 | -3,375 |
| Total other income (expense), net | -2,443 | -3,612 | -2,280 | -5,912 |
| Income Gain From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -19,900 | 4,639 | -25,100 | -57,722 |
| Income Tax Expense Benefit | 516 | 5,293 | -4,000 | -5,322 |
| Net loss | -20,393 | -589 | -21,165 | -52,400 |
| Unrealized gain (loss) on short-term investments | -1,027 | -88* | 241 | -98 |
| Unrealized gain on cash flow hedges | 1,702 | -195* | 534 | -612 |
| Foreign currency translation gains (losses) | -1,224 | 708 | 648 | 4,380 |
| Comprehensive loss | -20,942 | -164 | -19,742 | -48,730 |
| Basic EPS | -0.3 | -0.002 | -0.31 | -0.78 |
| Diluted EPS | -0.3 | -0.002 | -0.31 | -0.78 |
| Basic Average Shares | 68,397,000 | 68,034,000 | 67,652,000 | 67,050,000 |
| Diluted Average Shares | 68,397,000 | 68,034,000 | 67,652,000 | 67,050,000 |
TANDEM DIABETES CARE INC (TNDM)
TANDEM DIABETES CARE INC (TNDM)